Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Kazuhiro Yoshida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1408-0104; OpenAlex author ID A5074557622. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  2. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  3. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  4. A case report of a collision tumor composed of pancreatic ductal adenocarcinoma and peri-pancreatic mucosa-associated lymphoid tissue lymphoma. Co-author DOI 10.1186/s12957-023-02981-3↗
  5. Early Predictive Factors for Postoperative Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Cancer. Last author DOI 10.21873/cdp.10128↗
  6. Pancreaticoduodenectomy combined with splenectomy for a patient with pancreatic cancer and pancytopenia due to liver cirrhosis: Case report. Last author DOI 10.1016/j.ijscr.2021.105715↗
  7. [Efficacy of Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer Involving the Superior Mesenteric Artery]. Co-author PMID 26805071↗
  8. Novel strategy with gemcitabine for advanced pancreatic cancer. Last author DOI 10.5402/2011/936893↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshiya Higashi · 2 shared papers, 2021–2022 · strength 0.32
  2. Nobuhisa Matsuhashi · 2 shared papers, 2021–2022 · strength 0.32
  3. Hiroki Yamaue · 2 shared papers, 2023–2024 · strength 0.30
  4. Ippei Matsumoto · 2 shared papers, 2023–2024 · strength 0.30
  5. Manabu Kawai · 2 shared papers, 2023–2024 · strength 0.30
  6. Kazuya Yasui · 1 shared paper, 2025 · strength 0.19
  7. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19
  8. Yasuo Nagai · 1 shared paper, 2025 · strength 0.19
  9. Yuki Fujii · 1 shared paper, 2025 · strength 0.19
  10. Kazuyuki Matsumoto · 1 shared paper, 2025 · strength 0.19
  11. Yuzo Umeda · 1 shared paper, 2025 · strength 0.19
  12. Hironari Kato · 1 shared paper, 2025 · strength 0.19
  13. Kosei Takagi · 1 shared paper, 2025 · strength 0.19
  14. Ryuichi Yoshida · 1 shared paper, 2025 · strength 0.19
  15. Takeyoshi Nishiyama · 1 shared paper, 2025 · strength 0.19
  16. Motoyuki Otsuka · 1 shared paper, 2025 · strength 0.19
  17. Toshiyoshi Fujiwara · 1 shared paper, 2025 · strength 0.19
  18. Syuichiro Maruyama · 1 shared paper, 2023 · strength 0.16
  19. Ryuji Hirai · 1 shared paper, 2023 · strength 0.16
  20. Yosuke Inoue · 1 shared paper, 2024 · strength 0.16
  21. Xianjun Yu · 1 shared paper, 2024 · strength 0.16
  22. Satoshi Nara · 1 shared paper, 2024 · strength 0.16
  23. Naohiro Okano · 1 shared paper, 2024 · strength 0.16
  24. Shinichiro Takahashi · 1 shared paper, 2024 · strength 0.16
  25. Tomohisa Yamamoto · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.